Healthcare provider profile · identity verified

Timothy A Woods, MD

Internal Medicine · BALA CYNWYD, PA · NPI 1043229289

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	230	54
Atorvastatin Calcium	Atorvastatin Calcium	229	69
Rosuvastatin Calcium	Rosuvastatin Calcium	208	50
Sertraline Hcl	Sertraline Hcl	147	37
Lorazepam	Lorazepam	144	26
Metoprolol Succinate	Metoprolol Succinate	131	38
Metformin Hcl	Metformin Hcl	129	34
Losartan Potassium	Losartan Potassium	128	25
Levothyroxine Sodium	Levothyroxine Sodium	107	27
Prednisone	Prednisone	93	40
Omeprazole	Omeprazole	92	25
Zolpidem Tartrate	Zolpidem Tartrate	84	23
Tamsulosin Hcl	Tamsulosin Hcl	83	21
Simvastatin	Simvastatin	73	16
Azithromycin	Azithromycin	71	49
Escitalopram Oxalate	Escitalopram Oxalate	71	18
Clonazepam	Clonazepam	65	13
Lisinopril	Lisinopril	65	25
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	62	11
Furosemide	Furosemide	59	15
Gabapentin	Gabapentin	57	15
Hydrochlorothiazide	Hydrochlorothiazide	57	15
Pantoprazole Sodium	Pantoprazole Sodium	57	17
Albuterol Sulfate Hfa	Albuterol Sulfate	56	33
Eliquis	Apixaban	56	13
Ondansetron Hcl	Ondansetron Hcl	55	suppressed
Ezetimibe	Ezetimibe	53	16
Potassium Chloride	Potassium Chloride	53	16
Ozempic	Semaglutide	52	suppressed
Donepezil Hcl	Donepezil Hcl	51	suppressed
Valsartan	Valsartan	51	15
Trazodone Hcl	Trazodone Hcl	46	14
Diphenhydramine Hcl	Diphenhydramine Hcl	42	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	41	suppressed
Cephalexin	Cephalexin	39	26
Alprazolam	Alprazolam	38	17
Irbesartan	Irbesartan	38	suppressed
Metformin Hcl Er	Metformin Hcl	38	11
Methylprednisolone	Methylprednisolone	37	31
Oxycodone Hcl	Oxycodone Hcl	37	suppressed
Tramadol Hcl	Tramadol Hcl	37	11
Myrbetriq	Mirabegron	36	suppressed
Synthroid	Levothyroxine Sodium	35	suppressed
Mounjaro	Tirzepatide	34	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Amiodarone Hcl	Amiodarone Hcl	32	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	22
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Nebivolol Hcl	Nebivolol Hcl	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	13
Diazepam	Diazepam	29	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Famotidine	Famotidine	27	suppressed
Sodium Chloride	0.9 % Sodium Chloride	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	26	suppressed
Allopurinol	Allopurinol	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	15
Bupropion Hcl	Bupropion Hcl	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Celecoxib	Celecoxib	20	suppressed
Felodipine Er	Felodipine	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	11
Amiloride Hcl	Amiloride Hcl	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Fentanyl	Fentanyl	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	14
Ramipril	Ramipril	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Meloxicam	Meloxicam	16	suppressed
Mupirocin	Mupirocin	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	11
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Indapamide	Indapamide	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Finasteride	Finasteride	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error